Forte Biosciences (FBRX) Net Income towards Common Stockholders (2016 - 2020)
Historic Net Income towards Common Stockholders for Forte Biosciences (FBRX) over the last 5 years, with Q1 2020 value amounting to -$9.4 million.
- Forte Biosciences' Net Income towards Common Stockholders rose 4500.7% to -$9.4 million in Q1 2020 from the same period last year, while for Dec 2020 it was -$9.4 million, marking a year-over-year increase of 8520.85%. This contributed to the annual value of -$63.5 million for FY2019, which is 2974.36% down from last year.
- Forte Biosciences' Net Income towards Common Stockholders amounted to -$9.4 million in Q1 2020, which was up 4500.7% from -$10.6 million recorded in Q4 2019.
- In the past 5 years, Forte Biosciences' Net Income towards Common Stockholders registered a high of -$383000.0 during Q3 2018, and its lowest value of -$19.6 million during Q4 2018.
- Its 5-year average for Net Income towards Common Stockholders is -$11.4 million, with a median of -$10.0 million in 2017.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 9615.19% in 2018, then tumbled by 479164.49% in 2019.
- Quarter analysis of 5 years shows Forte Biosciences' Net Income towards Common Stockholders stood at -$8.5 million in 2016, then fell by 28.08% to -$10.8 million in 2017, then tumbled by 80.89% to -$19.6 million in 2018, then surged by 46.01% to -$10.6 million in 2019, then rose by 11.23% to -$9.4 million in 2020.
- Its Net Income towards Common Stockholders stands at -$9.4 million for Q1 2020, versus -$10.6 million for Q4 2019 and -$18.7 million for Q3 2019.